Allergen-specific immunotherapy, together with drug therapy, patient education, and allergen avoidance, is a cornerstone in the management of respiratory allergy, and it is now recognized as the only treatment capable of modifying the immune response to allergens.
The efficacy of subcutaneous immunotherapy (SCIT) for allergic respiratory diseases has been confirmed in systematic reviews and meta-analyses for asthma and recently for seasonal allergic rhinitis.
Click on the following link to see the full article:
